Name
Besremi
Alternate Names
Ropeginterferon alfa-2b-njft
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
none
NSC Number
None
Primary Site
None
Histology
Polycythemia vera
Remarks
November 15, 2021 The FDA approved Besremi (ropeginterferon alfa-2b-njft) injection to treat adults with polycythemia vera. Besremi is the first FDA-approved medication for polycythemia vera that patients can take regardless of their treatment history, and the first interferon therapy specifically approved for polycythemia vera.
Coding
This drug should be coded